Meng-Ju Wu

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Meng-Ju Wu

Oct 5, 2024, 13:35 | Insight

SI kinase to act as a key signaling mediator of a rare fusion oncogene involved in fibrolamellar carcinoma

Kei Sakamoto, Vice Director of Novo Nordisk Foundation, shared a post by Elizabeth McKenna, on…

Sep 30, 2024, 16:38 | Insight

New work on how DNAJB1-PRKACA fusion drives Fibrolamellar Carcinoma

Ilaria Gritti shared a post on X, by Elizabeth McKenna, about a recent paper published…

Aug 26, 2024, 20:59 | Blog

Meng-Ju Wu’s lab is seeking postdocs and research associates

Meng-Ju Wu, Instructor at Harvard Medical School and Massachusetts General Hospital, shared a post on…

Jul 15, 2024, 11:28 | Insight

Meng-Ju Wu: IDH1 inhibition activates tumor immunity by inducing dsDNA sensing

Meng-Ju Wu, Instructor at Harvard Medical School and Massachusetts General Hospital, shared on X about…

Jul 14, 2024, 06:22 | Insight

Anirban Maitra: Another spectacular study from Nabeel Bardeesy on Mutant IDH1 inhibition

Anirban Maitra shared a post on X about a recent paper by Nabeel Bardeesy et…

All: 5 Posts: 1 - 100

'

ctDNA after surgery for MMRd tumors can prevent cancer recurrence - Yelena Janjigian at AACR25

'

Top Growing Medical Universities in the Post-Soviet Region – BIGR 2025 Edition

'

Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab

'

POEM 2025 Scientific Meeting: Key Sessions, Workshops, and Why You Should Attend

'

10 Caring Notes from Pope Francis on Healthcare

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023